The Emerging Role of Nutritional Vitamin D in Secondary Hyperparathyroidism in CKD

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
cholecalciferol 8 nephrologydiseasesdrugs
chronic kidney disease 2 nephrologydiseases
paricalcitol 3 nephrologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
cholecalciferol 33887 total or free 25D represents the surrogate marker of vitamin D bioactivity [[119],[120]]. NVD, both the cholecalciferol and calcifediol supplements are effective in increasing the total and free 25D level and are associated
cholecalciferol 34081 level and are associated with serum PTH level decline [[121]]. In CKD patients, supplementing with cholecalciferol for 12 weeks had a significant increase (185%) in serum 25D concentration when compared with the placebo.
cholecalciferol 34259 concentration when compared with the placebo. Meanwhile, the PTH levels also tended to decrease after cholecalciferol supplementation [[122]]. More recently, Westerberg et al. reported high-dose cholecalciferol (8000 IU/day)
cholecalciferol 34352 after cholecalciferol supplementation [[122]]. More recently, Westerberg et al. reported high-dose cholecalciferol (8000 IU/day) in patients with CKD stage 3–4 halted the development of SHPT and did not increase the
cholecalciferol 34563 increase the risk of hypercalcemia and hyperphosphatemia [[123]]. In non-dialysis CKD patients with VDD, cholecalciferol supplementation was superior to ergocalciferol with a two-fold increase of circulating 25D level [[124]].
cholecalciferol 37647 treating SHPT if combined with calcitriol or calcimimetics in dialysis patients. We previously reported cholecalciferol in combination with paricalcitol for 15 weeks could effectively lower the PTH level in dialysis patients.
cholecalciferol 37808 could effectively lower the PTH level in dialysis patients. Furthermore, a dose of 5000 IU/week of cholecalciferol could maintain a serum 25D concentration > 30 ng/mL as early as after eight weeks of supplementation
cholecalciferol 37965 > 30 ng/mL as early as after eight weeks of supplementation [[16]]. In addition, we also found that cholecalciferol supplementation could additively reduce serum PTH levels, improve 25D levels, and improve femoral neck
paricalcitol 20986 [[85]]. After calcimimetics treatment, the oxyphil cell content was significantly higher than in the paricalcitol group (a less calcemic analog of calcitriol) [[80],[86]]. In addition, in a retrospective analysis,
paricalcitol 26860 [[84]].Our previous studies demonstrated that NVD had a positive benefit as an adjuvant therapy with paricalcitol /calcitriol and calcimimetics in treating SHPT in dialysis patients [[16],[17]]. These clinical studies
paricalcitol 37683 calcitriol or calcimimetics in dialysis patients. We previously reported cholecalciferol in combination with paricalcitol for 15 weeks could effectively lower the PTH level in dialysis patients. Furthermore, a dose of 5000
Select Disease Character Offset Disease Term Instance
chronic kidney disease 1827 c_y_huang_alex@yahoo.com.twPublication date (epub): 12/2018Publication date (collection): 12/2018AbstractIn chronic kidney disease (CKD), hyperphosphatemia induces fibroblast growth factor-23 (FGF-23) expression that disturbs renal
chronic kidney disease 3399 independent risk for all-cause mortality and cardiovascular mortality. The prevalence of SHPT within chronic kidney disease (CKD) population is highly variable, and dependent on the definition of SHPT, renal disease severity,

You must be authorized to submit a review.